SIFI launches NETILDEX(TM) Ophthalmic Gel: the first antibiotic-corticosteroid combination in single-dose gel
SIFI Group enhances and completes its offering with the launch of NETILDEX(TM) Ophthalmic Gel for the pharmaceutical treatment of ocular inflammations with or without the risk of infection, and of OXISTOP(TM), an innovative solution to ocular discomfort in dry eye disease.
Catania, June 17th, 2014 – SIFI, the leading Italian Eye Care company, enhances its wide offering with a new product: NETILDEX(TM) Ophthalmic Gel, the first antibiotic-corticosteroid combination in single-dose gel formulation.
“With the launch of the gel formulation, SIFI completes the NETILDEX(TM) line, our most important pharmaceutical in a key therapeutic area” explains Fabrizio Chines, Executive Chairman of SIFI SpA “Thanks to NETILDEX(TM) Gel we are now in a position to offer ophthalmologists and patients the most appropriate solution for all indications where a fixed anti-infective - anti-inflammatory combination is required”.
NETILDEX(TM) Ophthalmic Gel is a semi-solid pharmaceutical formulation containing dexamethasone disodium phosphate and netilmicin sulphate with the addition of Xanthan Gum, the gel thickening agent. This ophthalmic gel is specifically recommended when eye bandaging is required, in case of night administration, and for the management and treatment of the diseases affecting the accessory visual structures (adnexa of the eye) because of its prolonged permanence on the eyelid rim. Moreover the Xanthan gum properties make this pharmaceutical product specifically recommended in every postoperative condition where eye surgery has deeply altered the ocular surface and is necessary an important and effective hydration and lubrication of the eye surface.
Ophthalmic Gel is the only ophthalmic anti-infective - anti-inflammatory gel in single-dose presentation, which guarantees reduced contamination risks combined with the advantages of no preservative potentially hindering the delicate eye-system balances.
NETILDEX(TM) Ophthalmic Gel, being a semi-solid pharmaceutical formulation, is specifically recommended for the treatment of ocular adnexa diseases, such as blepharitis, an often underdiagnosed eye disorder that can strongly influence the successful outcome of eye surgery, as reported in recent scientific publications.
According to current clinical data, around a third of the patients undergoing anterior segment surgery may be diagnosed with blepharitis (anterior, posterior or mixed), even in sub-clinical forms. This condition can seriously endanger the outcome of eye surgery, although technically flawless.
International guidelines for the prevention of postoperative endophthalmitis issued by ESCRS and AAO, for example, highly recommend to treat a diagnosed blepharitis before eye surgery, including cataracts.
Commenting on SIFI’s latest additions Giampiero Alessi, Market Access Director, highlights that “In 2014 SIFI presents itself as a company in fast and dynamic recovery, focused on innovation and development, with a specific drive on expanding in foreign markets. We forecast that a third of our short term growth will come from Italy, whilst the remaining two thirds will be generated in emerging markets. Our presence is already strong in Turkey, Mexico and Romania and, with our new partner Nova Medica, we are re-launching our business in Russia”.
Another milestone in this new context is the launch of OXISTOP(TM), marketed by Eyelab, a SIFI Group company.
OXISTOP(TM) is a sterile balanced ophthalmic solution, hydrating and lubricant, containing Xanthan gum 0.2%. This new eye drop is recommended in all conditions of ocular discomfort related to oxidative stress. Xanthan gum is a natural polymer which has shown efficacy in reducing oxidative stress levels on the ocular surface, thanks to its unique chemical structure.
As reported in many clinical trials, oxidative stress is one of the main factors in inducing or worsening ocular discomfort.
OXISTOP is indicated for reducing eye discomfort symptoms due to: natural ageing processes, contact lenses wear, environmental factors such as pollution and continued exposure to UV rays and eye surgery.
The single-dose preservative-free formulation provides an additional benefit for this new product, which represents a useful contribution for the ophthalmologists’ daily clinical practice.